로딩 중…
지수 로딩 중…
Veracyte, Inc.
VCYT· NASDAQ· Health Care· Health Care Equipment & Services
$53.63+4.56%
2026-06-18
Price Chart
Veracyte, Inc.+99.96%
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $4.28B |
| Revenue | $542M |
| Net Income | $88M |
| Total Assets | $1.44B |
| Net Assets | $1.34B |
| Employees | 755 |
| Value | |
| P/E | 48.62x |
| P/B | 3.18x |
| PEG | 0.16x |
| P/S | 7.90x |
| EV/EBITDA | 38.22x |
| FCF Yield | 3.62% |
| Profitability | |
| ROE | 6.55% |
| ROA | 6.13% |
| Op. Margin | 12.45% |
| Revenue Growth | 21.49% |
| Earnings Growth | 307.36% |
| Financial Health | |
| Debt Ratio | 6.84% |
| Total Debt | $39M |
| FCF | $155M |
| Cash | $263M |
| Current Ratio | 9.31x |
| Net Debt/EBITDA | -2.11x |
| Performance | |
| 1Y Return | 99.96% |
| 1M Return | 28.64% |
| From 52W High | -0.33% |
| 1Y MDD | -39.23% |
| Trading | |
| Volume | 3,049,635 shares |
| Trading Value | $162M |
| Per Share | |
| EPS | $0.84 |
| BPS | $16.54 |
Company Info
CEO Mr. Marc A. Stapley
Employees 755
HQ South San Francisco, United States
Website https://www.veracyte.com
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.